Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Manufacturing

Accelerating self-administration and homecare with large-volume prefillable glass syringe

SCHOTT Pharma launches 5.5 ml syringe compatible with autoinjectors to enable comfortable home injections
Manufacturing

Aenova expands sterile fill & finish manufacturing at its Latina site

New line to boost biologics capacity and support a wide range of container formats
Research & Development

Certified biobased resins bring sustainable lab filtration to Cytiva’s customers

Certified materials enable labs to choose more sustainable options without changing workflows or compromising performance
Research & Development

Syngene International plans to add bioconjugation suite for end-to-end antibody-drug conjugates development

Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services
Research & Development

Cellarity unveils AI-driven framework for cell state-correcting drug discovery in the journal Science

Biotech innovator Cellarity publishes a breakthrough blueprint integrating multiomics and machine learning to accelerate discovery of complex disease therapies, alongside the release of three open-access single-cell datasets
Subscribe now